Get started
Work

562P First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort

Year: 2023
Type: article
DOI: 10.1016/j.annonc.2023.10.640
Authors: Y. Cheng, Y. Yu, Y. Fan, L. Jiang, L. Wu, J. Hu, J. Wang, W. Yao, Z. Han, Y. Yao, J. Fang, M. Sun, Q. Wang, Y. Pan, R. Wu, J. Liu, Y. Liu, D. Kulkarni, X. Huang, P.A. Jänne
Institutions: Jilin Province Tumor Hospital, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, Zhejiang Cancer Hospital, Shanghai Jiao Tong University, Shanghai Chest Hospital, Hunan Cancer Hospital, Shanghai Medical College of Fudan University, Fudan University, Zhongshan Hospital, Fudan University Shanghai Cancer Center, Sichuan Cancer Hospital, Xinjiang Medical University, Tumor Hospital of Xinjiang Medical University, First Affiliated Hospital of Xi'an Jiaotong University, Peking University Cancer Hospital, Shandong University, Jinan Central Hospital, Shandong First Medical University, Zhengzhou University, Henan Cancer Hospital, University of Science and Technology of China, Sheng Jing Hospital, AstraZeneca (United Kingdom), Dana-Farber Cancer Institute
Language: English
Field: Medicine
Open Access status: bronze
Funder: AstraZeneca
OpenAlex ID: W4389280237
FWCI: 0.161
Cites:
Cited by: 1
Related to: 10